跳转至内容
Merck
CN

S8626

磺胺嘧啶

99.0-101.0%

别名:

N-2-嘧啶基-4-氨基苯磺酰胺, N1-(嘧啶-2-基)磺胺

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C10H10N4O2S
化学文摘社编号:
68-35-9
分子量:
250.28
UNSPSC Code:
51283908
NACRES:
NA.85
PubChem Substance ID:
24899802
EC Number:
200-685-8
Beilstein/REAXYS Number:
6733588
MDL number:
MFCD00006065

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

InChI key

SEEPANYCNGTZFQ-UHFFFAOYSA-N

SMILES string

Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2

description

Solubility - Practically insoluble in water, slightly soluble in acetone, very slightly soluble in ethanol (96 per cent). It dissolves in solutions of alkali hydroxides and in dilute mineral acids.

assay

99.0-101.0%

form

powder or crystals

color

white to faint yellow, faint pink

mp

253 °C (dec.) (lit.)

solubility

96% ethanol: very slightly soluble, acetone: slightly soluble, water: practically insoluble

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria, mycoplasma

mode of action

DNA synthesis | interferes, enzyme | inhibits

Quality Level

200

正在寻找类似产品? 访问 产品对比指南

相关类别

General description

化学结构式：磺酰胺

Application

磺胺嘧啶是一种短效磺胺类药物，常用于与乙胺嘧啶合用治疗获得性免疫缺陷综合征患者的弓形虫病。也用于治疗新生儿先天性感染 。在研究再活化弓形虫病的鼠模型时，磺胺嘧啶已被用于控制急性感染 。

Biochem/physiol Actions

磺胺嘧啶是一种磺胺类抗生素，通过抑制二氢喋呤合成酶而阻断二氢叶酸的合成。磺胺嘧啶是细菌合成叶酸所需的对氨基苯甲酸 (PABA) 的竞争性抑制剂 。对革兰氏阳性菌、革兰氏阴性菌和衣原体有效。耐药模式是通过改变二氢喋呤合成酶或叶酸合成的替代途径。

Other Notes

将容器密闭保存在干燥和通风良好的地方。储存类别 (TRGS 510)：非易燃固体

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2

存储类别

11 - Combustible Solids

wgk

WGK 2

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000504482
0000504482
0000486684
0000486684
0000486683

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sven Jechalke et al.
Applied and environmental microbiology, 79(5), 1704-1711 (2013-01-15)
Spreading manure containing antibiotics in agriculture is assumed to stimulate the dissemination of antibiotic resistance in soil bacterial populations. Plant roots influencing the soil environment and its microflora by exudation of growth substrates might considerably increase this effect. In this
Romain Sonneville et al.
Neurology, 79(17), 1762-1766 (2012-10-12)
Cerebral toxoplasmosis remains a common neurologic complication in patients with AIDS. In this study, we aimed to characterize the prognosis of patients with HIV infection with severe forms of cerebral toxoplasmosis and to investigate the effects of adjunctive steroids on
Tamim M Niazi et al.
International journal of radiation oncology, biology, physics, 84(3), e305-e310 (2012-06-02)
For patients with anal canal and advanced rectal cancer, chemoradiation therapy is a curative modality or an important adjunct to surgery. Nearly all patients treated with chemoradiation experience some degree of radiation-induced dermatitis (RID). Prevention and effective treatment of RID
Ildiko R Dunay et al.
Antimicrobial agents and chemotherapy, 53(10), 4450-4456 (2009-07-29)
Immunocompromised patients are at risk of developing toxoplasmosis, and although chemotherapy is available, standard treatments are often complicated by severe side effects. Artemisinin is a new highly potent antimalarial drug that has activity against Toxoplasma gondii in vitro. However, artemisinin
Pascale Meneceur et al.
Antimicrobial agents and chemotherapy, 52(4), 1269-1277 (2008-01-24)
Sulfadiazine, pyrimethamine, and atovaquone are widely used for the treatment of severe toxoplasmosis. Their in vitro activities have been almost exclusively demonstrated on laboratory strains belonging to genotype I. We determined the in vitro activities of these drugs against 17
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持